(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
04 June 2020 (04.06.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/112588 A1

(51) International Patent Classification:
A61K 47/68 (2017.01)

(21) International Application Number:
PCT/US2019/062913

(22) International Filing Date:
25 November 2019 (25.11.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/773,708 30 November 2018 (30.11.2018) US

(71) Applicant: **BRISTOL-MYERS SQUIBB COMPANY** [US/US]; Route 206 and Province Line Road, Princeton, New Jersey 08543 (US).

(72) Inventors: **STROP, Pavel**; c/o Bristol-Myers Squibb Company, 700 Bay Road, Redwood City, California 94063 (US). **RAO-NAIK, Chetana**; c/o Bristol-Myers Squibb Company, 700 Bay Road, Redwood City, California 94063 (US). **DENG, Xiaodi**; c/o Bristol-Myers Squibb Company, 700 Bay Road, Redwood City, California 94063 (US). **SHEPPARD, Paul O.**; c/o Bristol-Myers Squibb Company, 700 Bay Road, Redwood City, California 94063 (US). **HOLDER, Patrick G.**; 39 Arroyo Avenue, Piedmont, California 94611 (US). **YAMAZOE, Sayumi**; c/o Bristol-Myers Squibb Company, 700 Bay Road, Redwood City, California 94063 (US).

(74) Agent: **CHAO, Yuan** et al.; Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: ANTIBODY COMPRISING A GLUTAMINE-CONTAINING LIGHT CHAIN C-TERMINAL EXTENSION, CONJUGATES THEREOF, AND METHODS AND USES

(57) Abstract: An antibody has a glutamine-containing extension at the C-terminus of a light chain thereof, making it suitable for conjugation via transglutaminase-mediated transamidation.

WO 2020/112588 A1